Erhöhte kardiovaskuläre Mortalität in der (späteren) Postmenopause

Global status report on noncommunicable diseases 2010. World Health Organization, Geneva

NIH (1992) Chartbook on cardiovascular, lung and blood diseases. U.S. Department of Health and Human Services, Washington

Kramarow et al (1999) Health, United States, 1999. Natl Cent Health Stat 164:167

Ries et al (1999) SEER cancer statistics review, 1973–1996. National Cancer Institute

Turnstall-Pedoe H (1998) Myth and paradox of coronary risk and the menopause. Lancet 351:1425–1427

Lobo RA (1995) Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173:982–985

Framingham Study, US „Department of Health, Education, & Welfare“ (DHEW), No.74, 1974

Hu FB, Grodstein F, Hennekens CH et al (1999) Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 159:1061–1066

Rosenberg L, Hennekens CH, Rosner B et al (1981) Early menopause and risk of cardiovascular infarction. Am J Obstet Gynecol 139:47–51

Mueck AO, Seeger H, Wallwiener D (2003) Rauchen, Estradiolstoffwechsel und Hormonsubstitution. Geburtsh Frauenheilk 63:213–222

Spencer CP, Godsland IF, Stevenson JC (1997) Is there a menopausal metabolic syndrome? Gynecol Endocr 11:341–355

Salpeter SR, Walsh JME, Ormiston TM et al (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8:538–554

Lindoff C, Petersson F, Lecander I et al (1993) Passage of menopause is followed by haemostatic changes. Maturitas 17:17–22

Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913

Vasan RS, Larson MG, Leip EP et al (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345:1291–1297

Brownley KA, Hinderliter AL, West SG et al (2004) Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 190:1052–1058

Seeger H, Mueck AO, Lippert TH (1995) Comparison of the effect of estradiol with calcium channel-blockers – in vitro investigations of calcium influx in human aortic smooth muscle cells. Pharm Pharmacol Letters 5:132–134

Mueck AO, Seeger H (2007) Kardiovaskuläre Risiken unter HRT in der Postmenopause. Gynaekol Endokrinol 5:120–126

Mueck AO, Seeger H (2004) Effect of hormone therapy on BP in normotensive and hypertensive women. Maturitas 49:189–203

Davis SR, Castelo-Branco C, Chedraui P et al (2012) Understanding weight gain at menopause. Climacteric 15:419–429

Lobo R (2008) Metabolic syndrome and the role of hormones. Maturitas 60:10–18

Hanke H, Hanke S, Ickrath O et al (1997) Estradiol concentrations in premenopausal women with coronary heart disease. Coron Artery Dis 8:511–515

Matthews KA, Crawford Sl, Chae CU et al (2009) Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54:2366–2373

Lippert TH, Mueck AO, Ginsburg J (1998) Sex steroids and the cardiovascular system. Parthenon Publishing Group, New York, S 35–95

Mueck AO (2003) Primär- und Sekundärprävention kardiovaskulärer Erkrankungen durch Hormonsubstitution in der Postmenopause. Gynäkologe 36:197–209

Mueck AO, Seeger H, Lippert TH (1996) Calciumantagonistic effect of natural and synthetic extrogens – investigations on a nongenomic mechanism of direct vascular action. Int J Clin Pharm Ther 32:424–427

Mueck AO, Seeger H, Wallwiener D (2002) Medroxyprogesterone acetate vs. norethisterone: effect on estradiol induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 9:273–281

Mueck AO, Seeger H, Lippert TH (1998) Estradiol inhibits LDL oxidation: do the progestins medroxyprogesterone acetate and norethisterone acetate influence this effect? Clin Exp Obstet Gynecol 25:26–28

Mueck AO, Seeger H, Lippert C, Wallwiener D (2001) Angiogenetic and antiangiogenetic effects of estradiol and of its metabolites. J Clin Basic Cardiol 4:153–155

Lippert TH, Seeger H, Mueck AO (1999) Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric 1:296–301

Lippert TH, Seeger H, Mueck AO (1998) Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause. Horm Metab Res 30:598–601

Mikkola TS, Clarkson TB (2002) Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53:605–619

Hanke H, Hanke S, Brehme U et al (1996) Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 121:129–138

Hanke H, Hanke S, Finking G et al (1996) Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. – Quantification of cellular proliferation by bromodeoxy-uridine. Circulation 94:175–181

Barrett-Connor E, Laughlin G (2005) Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 12:40–48

Manson JE, Allison MA, Rossouw JE et al (2006) Estrogen therapy and coronary-artery calcification. N Engl J Med 356:2591–2602 (Int J Epidemiol 2006; 35:731–738)

Bourne T, Hillard TC, Whitehead MI et al (1990) Oestrogens, arterial status, and postmenopausal women. Lancet 335:1470–1471

Gangar KF, Vyas S, Whitehead M et al (1991) Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 338:839–842

LaCroix AZ, Chlebowski RT, Manson JE et al (2011) Health outcomes after stopping con-jugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized con-trolled trial. JAMA 305:1305–1314

Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–1477

Grodstein F, Manson JE, Stampfer KJ (2006) Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 15:35–44

Schierbeck LL, Rejnmark L, Landbo et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409

Salpeter SR, Walsch JME, Greyber E, Salpeter EE (2006) Coronary heart disease events associated with hormone therapy in younger and older women. A meta analysis. J Gen Intern Med 21:401–410

Stampfer MJ, Grodstein F (1999) Role of hormone replacement in cardiovascular disease. In: Lobo RA (Hrsg) Treatment of the postmenopausal womam: basic and clinical aspects, 2. Aufl. Lippincott Williams & Wilkins, Philadelphia, S 361–367

Grodstein F, Stampfer MJ, Colditz GA et al (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769–1775

Mueck AO (2013) Anwendungsempfehlungen für die gynäkologische Praxis zur Hormonsubstitution im Klimakterium und in der Postmenopause. Aktualisierte Empfehlungen, Oktober 2012. Gyn Endokrinol 11:58–62

Ortmann O (2009) Hormontherapie in der Peri- und Postmenopause. Kurzversion der interdisziplinären S3-Leitlinie. Frauenarzt 10:840–85

Walsh JME, Pignone M (2004) Drug treatment of hyperlipidemia in women. JAMA 291:2243–2252

Petretta M, Gostanzo P, Perrone-Filardi P, Chiariello M (2010) Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. lnt J Cardiol 138:25–31

Villiers TJ de et al (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:316–337